Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
It belongs to a new generation of incretin-based compounds often called triple agonists because of their ability to simultaneously activate three distinct metabolic receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR)
The STEP-1 trial tested semaglutide at 2.4mg weekly in 1,961 adults without diabetes
Parke-Davis/Warner-Lambert) was approved by the Food and Drug Administration
In both trials, the most common adverse effects were GI-related and consistent with the GLP-1 class, and all resolved or were manageable with slow titration
US$ 26.30
US$ 27.37
US$ 23.07
US$ 23.96
